(662)-236-2609


Research
ELI has successfully executed research projects for federal and private organizations ranging from inception of concept to product development and patent. In addition, ELI participates in product testing, pharmacokinetic studies, stability studies, and method development for a wide range of clients. The selected patents listed below show the diversity of research projects performed at ELI:

  • ElSohly, Mahmoud A.; Gul, Waseem; Selected Artemisinin Dimers for the Treatment of Lashmaniasis, U.S. Patent 12,156,915 B2, issued December 3, 2024.
  • Hamann, Curt.; ElSohly, Mahmoud A.; Gul, Waseem; Hage, Raymond J.; Patches Comprising Urushiol, Test Panels Comprising the Same, and Methods of Using the Same, U.S. Patent 11,666,667 B2, issued June 6, 2023.
  • ElSohly, Mahmoud A.; Gul, Waseem; Radwan, Mohamed M.; Wanas, Amira S.; Isolation of Pure Cannabinoids from Cannabis, U.S. Patent 11,117,852 B2, issued September 14, 2021.
  • ElSohly, Mahmoud A.; Majumdar, Soumyajit; Gul, Waseem; Ashfaq, Mohammad K.; Sufka, Kenneth J.; Harris, Hannah M.; Biologically Active Cannabidiol Analogs, U.S. Patent 10,709,681 B2 issued July 14, 2020.
  • ElSohly, Mahmoud A.; Gul, Waseem; Cole, Jeptha N.; Resveratrol Esters, U.S. Patent 10,099,995 B2, issued October 16, 2018.
  • ElSohly, Mahmoud A.; Gul, Waseem; Repka, Michael A.; Majumdar, Soumyajit; Ashfaq, Mohammad K.; Compositions Containing Delta-9-THC-Amino Acid Esters and Process of Preparation, U.S. Patent 9,630,941 B2, issued April 25, 2017.  
  • ElSohly, Mahmoud A.; Gul, Waseem; Ashfaq, Mohammad K.; Manly, Susan P.; Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis, U.S. Patent 9,029,417 B2, issued May 12, 2015.
  • ElSohly, Mahmoud A.; Gul, Waseem; Anticancer and Antiprotozoal Dihydroartemisinene and Dihydroartemisitene Dimers with Desirable Chemical Functionalities, U.S. Patent 7,842,720 B2, issued November 30, 2010. 
  • Salamone, Salvatore J.; Courtney, Jodi B.; Lundell, Gregory D.; ElSohly, Mahmoud A.; Gul, Waseem; Docetaxel Immunoassay, U.S. Patent 7,459,281 B2, issued December 2, 2008.
  • Salamone, Salvatore J.; Courtney, Jodi B.; Stocker, Dennis; ElSohly, Mahmoud A.; Gul, Waseem; Taxol Immunoassay, U.S. Patent 7,175,993 B2, issued February 13, 2007.
  • ElSohly, Mahmoud A.; Ross, Samir A.; Galal, Ahmed M.; Dihydroartemisinin and Dihydroartemisitene Dimers as Anti-Cancer and Anti-Infective Agents, U.S. Patent 7,098,242, issued August 29, 2006
  • Elsohly, Mahmoud A.; Gul, Waseem; Anticancer and Antiprotozoal Dihydroartemisinin and Dihydroartemisitene Dimers with Desirable Chemical Functionalities, European Patent WO 2006/002105 A1, issued January 5, 2006.
  • ElSohly, Mahmoud A.; Ross, Samir A., Galal, Ahmed M.; Dihydroartemisinin and Dihydroartemisitene Dimers as Anti-Cancer and Anti-Infective Agents, U.S. Patent 6,790,863 B2, issued September 14, 2004.
  • Pasco, David; Pugh, Nirmal; Ross, Samir A.; ElSohly, Mahmoud A.; Potent Immunostimulants from Micro-Algae, South Aftican Patent No. 2003/1050, issued July 28, 2004, New Zealand Patent No. 523695, issued November 11, 2004.
  • ElSohly, Mahmoud A.; Samir Ross; and Shixia Feng; Method of Preparing delta-9-tetrahydrocannabinol esters, Australia Patent No. 770382, issued June 17, 2004.
  • ElSohly, Mahmoud A.; Samir Ross; Method of preparing delta-9-tetrahydrocannabinol, Australia Patent No. 763700, issued November 13, 2003.
  • ElSohly, Mahmoud A.; Samir Ross; Method of preparing delta-9-tetrahydrocannabinol, U.S. Patent 6,365,416 B1, issued April 2, 2002.
  • ElSohly, Mahmoud A.; Samir Ross; and Shixia Feng; Method of Preparing delta-9-tetrahydrocannabinol esters, U.S. Patent 6,008,383, issued December 28, 1999.
  • ElSohly, Mahmoud A.; Stable Suppository Formulations Effecting Bioavailability of Delta-9-THC, U.S. Patent 5,509,037 issued April 16, 1996.
  • ElSohly, Mahmoud A.; and R. Brenneisen, Method of Identifying Country of Origin of Cannabis, U.S. Patent 5,252,490, issued October 12, 1993,
  • ElSohly, Mahmoud A.; and Thomas L. Little, Jr., Deuterated Cannabinoids as Standards for the Analysis of Tetrahydrocannabinol and its Metabolites in Biological Fluids, U.S. Patent 4,036,014, issued July 30, 1991.
Staff members at ELI have established expertise in the areas of analysis of a variety of drugs and their metabolites including but not limited to marijuana and Cannabinoids, coca (leaves, paste, and cocaine), opiates, barbiturates, amphetamines, phencyclidine, benzodiazepines (including flunitrazepam), gamma hydroxybutyrate, and other drugs of abuse.

Technical staff members are well trained and have participated in the execution of a variety of research projects in the drug abuse area. Every member of the ELI team is cognizant of the importance and implications of drug testing and research, the forensic aspects of it, and the confidentiality of the test results.

ElSohly Laboratories Financial Conflict of Interest (FCOI) Policy:
eli_fcoi_policy.pdf